Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients

High mobility group B1 (HMGB1) is a protein that is released from dying cancer cells in the context of immunogenic cell death (ICD). A recent study performed on patients with head and neck squamous cell carcinomas (HNSCC) reports that a chemoradiotherapy-induced increase in circulating HMGB1 levels...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Guido Kroemer, Oliver Kepp
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	immunotherapy immunogenic cell death damage-associated molecular pattern Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d1c3818d0e244f189784f14b906aeefd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d1c3818d0e244f189784f14b906aeefd
record_format	dspace
spelling	oai:doaj.org-article:d1c3818d0e244f189784f14b906aeefd2021-11-26T11:19:49ZRadiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients2162-402X10.1080/2162402X.2021.2005859https://doaj.org/article/d1c3818d0e244f189784f14b906aeefd2021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/2162402X.2021.2005859https://doaj.org/toc/2162-402XHigh mobility group B1 (HMGB1) is a protein that is released from dying cancer cells in the context of immunogenic cell death (ICD). A recent study performed on patients with head and neck squamous cell carcinomas (HNSCC) reports that a chemoradiotherapy-induced increase in circulating HMGB1 levels predicts favorable outcome, echoing prior studies on neoadjuvant treatment of breast and rectal cancer in which the dynamics of HMGB1 plasma levels also have prognostic value. Hence, a therapy-induced rise in HMGB1 may be interpreted as a clinical sign of ICD and therapeutic response.Guido KroemerOliver KeppTaylor & Francis Grouparticleimmunotherapyimmunogenic cell deathdamage-associated molecular patternImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENOncoImmunology, Vol 10, Iss 1 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immunotherapy immunogenic cell death damage-associated molecular pattern Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	immunotherapy immunogenic cell death damage-associated molecular pattern Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Guido Kroemer Oliver Kepp Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
description	High mobility group B1 (HMGB1) is a protein that is released from dying cancer cells in the context of immunogenic cell death (ICD). A recent study performed on patients with head and neck squamous cell carcinomas (HNSCC) reports that a chemoradiotherapy-induced increase in circulating HMGB1 levels predicts favorable outcome, echoing prior studies on neoadjuvant treatment of breast and rectal cancer in which the dynamics of HMGB1 plasma levels also have prognostic value. Hence, a therapy-induced rise in HMGB1 may be interpreted as a clinical sign of ICD and therapeutic response.
format	article
author	Guido Kroemer Oliver Kepp
author_facet	Guido Kroemer Oliver Kepp
author_sort	Guido Kroemer
title	Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
title_short	Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
title_full	Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
title_fullStr	Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
title_full_unstemmed	Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
title_sort	radiochemotherapy-induced elevations of plasma hmgb1 levels predict therapeutic responses in cancer patients
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/d1c3818d0e244f189784f14b906aeefd
work_keys_str_mv	AT guidokroemer radiochemotherapyinducedelevationsofplasmahmgb1levelspredicttherapeuticresponsesincancerpatients AT oliverkepp radiochemotherapyinducedelevationsofplasmahmgb1levelspredicttherapeuticresponsesincancerpatients
_version_	1718409500670558208

Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients

Ejemplares similares